PMID- 35371311
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220405
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 13
IP  - 5
DP  - 2022
TI  - PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
PG  - 1501-1511
LID - 10.7150/jca.61498 [doi]
AB  - Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a highly 
      aggressive malignant tumor with an extremely poor prognosis in digestive tumors. 
      Pyrroline-5-carboxylate reductase 1 (PYCR1) plays an important role in tumor 
      development. Therefore, we aimed to explore the effect of PYCR1 on the growth of 
      PDAC cells. Methods: Tumor tissues and adjacent normal pancreatic tissues were 
      collected from 89 patients with PDAC. And immunohistochemistry (IHC) was used to 
      analyze the expression level of PYCR1 in both. RNA interference was used to 
      inhibit the expression of PYCR1 in PANC- 1 and AsPC-1 cells. After infection, the 
      expression of PYCR1 protein was detected by Western blot. The proliferation and 
      growth of PDAC cells were detected by Celigo analysis, MTT, and clone formation 
      assay. Cell apoptosis was analyzed by flow cytometry. Furthermore, the effect of 
      PYCR1 interference on tumor growth was evaluated in vivo through injecting tumor 
      cells subcutaneously into nude mice. Results: The expression of PYCR1 in 
      pancreatic cancer tissues was significantly higher than in paired adjacent normal 
      pancreatic tissues (P <0.01). In vitro, the downregulation of PYCR1 expression 
      significantly inhibited the cell proliferation and colony formation, and 
      increased apoptosis in PANC-1 cells and AsPC-1 cells compared with the shCtrl 
      group (P <0.01). And in vivo, PYCR1 interference also significantly inhibited 
      tumor growth both in the tumor volume and weight. Conclusion: PYCR1 interference 
      was able to inhibit cell proliferation and promote cell apoptosis of pancreatic 
      cancer. The PYCR1 may serve as a potential therapeutic and prognostic biomarker 
      for the treatment of pancreatic cancer.
CI  - (c) The author(s).
FAU - Wang, Huanyu
AU  - Wang H
AD  - Department of General Surgery, Xuhui District Central Hospital, Shanghai, China.
FAU - Mao, Weilin
AU  - Mao W
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
AD  - Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Lou, Wenhui
AU  - Lou W
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
AD  - Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Jin, Dayong
AU  - Jin D
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
AD  - Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Wu, Wenchuan
AU  - Wu W
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
AD  - Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Wang, Dansong
AU  - Wang D
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
AD  - Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Kuang, Tiantao
AU  - Kuang T
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
AD  - Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Rong, Yefei
AU  - Rong Y
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
AD  - Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Xu, Xuefeng
AU  - Xu X
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
AD  - Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
AD  - Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20220228
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC8965111
OTO - NOTNLM
OT  - PYCR1
OT  - Pancreatic ductal adenocarcinoma
OT  - Prognosis
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2022/04/05 06:00
MHDA- 2022/04/05 06:01
PMCR- 2022/01/01
CRDT- 2022/04/04 05:29
PHST- 2021/04/11 00:00 [received]
PHST- 2022/01/16 00:00 [accepted]
PHST- 2022/04/04 05:29 [entrez]
PHST- 2022/04/05 06:00 [pubmed]
PHST- 2022/04/05 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - jcav13p1501 [pii]
AID - 10.7150/jca.61498 [doi]
PST - epublish
SO  - J Cancer. 2022 Feb 28;13(5):1501-1511. doi: 10.7150/jca.61498. eCollection 2022.